Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity.
Histone Methyltransferases
/ antagonists & inhibitors
Humans
Immunity, Heterologous
/ drug effects
Immunity, Innate
Interleukin-6
/ metabolism
Leukocytes, Mononuclear
/ immunology
Pemetrexed
/ pharmacology
Tuberculosis Vaccines
/ immunology
Tumor Necrosis Factor-alpha
/ metabolism
Vaccines, DNA
Vaccinia
/ immunology
Vaccinia virus
/ genetics
Viral Vaccines
/ immunology
Heterologous effects
Modified Vaccinia Ankara
Trained immunity
Vaccinia
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
12
07
2018
accepted:
21
09
2018
pubmed:
6
2
2019
medline:
13
9
2019
entrez:
6
2
2019
Statut:
ppublish
Résumé
Vaccines such as Vaccinia or BCG have non-specific effects conferring protection against other diseases than their target infection, which are likely partly mediated through induction of innate immune memory (trained immunity). MVA85A, a recombinant strain of modified Vaccinia Ankara (MVA), has been suggested as an alternative vaccine against tuberculosis, but its capacity to induce positive or negative non-specific immune effects has not been studied. This study assesses whether Vaccinia and MVA are able to induce trained innate immunity in monocytes. Human primary monocytes were primed in an in vitro model with Vaccinia or MVA for 1 day, after which the stimulus was washed off and the cells were rechallenged with unrelated microbial ligands after 1 week. Heterologous cytokine responses were assessed and the capacity of MVA to induce epigenetic changes at the level of cytokine genes was investigated using chromatin immunoprecipitation and pharmacological inhibitors. Monocytes trained with Vaccinia showed significantly increased IL-6 and TNF-α production to stimulation with non-related stimuli, compared to non-trained monocytes. In contrast, monocytes primed with MVA showed significant decreased heterologous IL-6 and TNF-α responses, an effect which was abrogated by the addition of a histone methyltransferase inhibitor. No effects on H3K4me3 were observed after priming with MVA. It can be thus concluded that Vaccinia induces trained immunity in vitro, whereas MVA induces innate immune tolerance. This suggests the induction of trained immunity as an immunological mechanism involved in the non-specific effects of Vaccinia vaccination and points to a possible explanation for the lack of effect of MVA85A against tuberculosis.
Identifiants
pubmed: 30719592
doi: 10.1007/s10096-018-03449-z
pii: 10.1007/s10096-018-03449-z
doi:
Substances chimiques
IL6 protein, human
0
Interleukin-6
0
MVA 85A
0
TNF protein, human
0
Tuberculosis Vaccines
0
Tumor Necrosis Factor-alpha
0
Vaccines, DNA
0
Viral Vaccines
0
Pemetrexed
04Q9AIZ7NO
Histone Methyltransferases
EC 2.1.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
449-456Subventions
Organisme : Danmarks Grundforskningsfond
ID : DNRF108
Organisme : European Research Council
ID : #310372
Pays : International
Organisme : Koninklijke Nederlandse Akademie van Wetenschappen
ID : Spinoza Grant
Références
J Infect Dis. 2014 Jun 1;209(11):1731-8
pubmed: 24436454
J Virol. 2006 Oct;80(20):9977-87
pubmed: 17005676
Clin Infect Dis. 2015 Nov 15;61(10):1504-11
pubmed: 26219694
Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):423-30
pubmed: 12818626
BMJ. 2010 Nov 30;341:c6495
pubmed: 21118875
Int J Epidemiol. 2017 Apr 1;46(2):695-705
pubmed: 27380797
PLoS One. 2006 Dec 20;1:e101
pubmed: 17183634
Immunology. 2014 Apr;141(4):506-13
pubmed: 24754048
J Pediatr. 2015 Jul;167(1):155-62.e1-2
pubmed: 25957979
Vaccine. 2013 Sep 6;31(39):4231-4
pubmed: 23523404
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42
pubmed: 22988082
Vaccine. 2006 Jul 17;24(29-30):5718-25
pubmed: 16720061
Clin Infect Dis. 2004 Jun 15;38(12):1749-53
pubmed: 15227622
J Immunol. 1994 Mar 15;152(6):2652-9
pubmed: 8144873
Lancet. 2013 Mar 23;381(9871):1021-8
pubmed: 23391465
Lancet Respir Med. 2015 Mar;3(3):190-200
pubmed: 25726088
Eur J Immunol. 2013 Aug;43(8):2114-25
pubmed: 23661549
Clin Infect Dis. 2013 Jul;57(2):283-9
pubmed: 23572484
Infect Immun. 1999 Apr;67(4):1553-9
pubmed: 10084986
Cell Host Microbe. 2012 Aug 16;12(2):223-32
pubmed: 22901542
J Clin Invest. 1998 Nov 1;102(9):1645-52
pubmed: 9802878
Cancer Causes Control. 2009 Jul;20(5):517-23
pubmed: 19011978
J Invest Dermatol. 2002 Sep;119(3):570-5
pubmed: 12230497
J Immunol. 1982 Nov;129(5):2239-43
pubmed: 6126504
J Infect Dis. 2011 Jul 15;204(2):245-52
pubmed: 21673035
Cell. 2007 Sep 7;130(5):918-31
pubmed: 17803913
Semin Immunol. 2014 Dec;26(6):512-7
pubmed: 25444548
Clin Vaccine Immunol. 2016 Dec 5;23(12):926-933
pubmed: 27733422
Vaccine. 2007 Aug 29;25(35):6458-73
pubmed: 17651872
J Immunol Methods. 2003 Jul;278(1-2):283-92
pubmed: 12957415
Virology. 2001 Sep 15;288(1):175-87
pubmed: 11543670
Nat Rev Immunol. 2016 Jun;16(6):392-400
pubmed: 27157064
J Leukoc Biol. 2015 Sep;98(3):347-56
pubmed: 26150551
Infect Immun. 1978 Sep;21(3):886-95
pubmed: 213391